Are you prepared for a 'Vaccine' Crash'?

INO.com

The below offer is brought to you by Altimetry Research

Dear Trading Forex,

When Covid-19 hit last March, investors rushed into one specific part of the tech market:

Stay-at-home stocks.

These stocks were among the biggest winners of 2020.

A few have recently hit new highs...

The so-called experts are currently recommending you buy more.

But I must warn you:

Many of these Covid darlings are in deep trouble.

When a vaccine starts working – these stocks will drop like a rock.

In fact, I believe the Vaccine Crash will be worse than last March.

I'm estimating a potential 75% drop in this niche sector.

Most investors are totally unaware how heavily overweighted they are in stay-at-home stocks.

That's why I just released this urgent briefing on the Vaccine Crash.

I'll show you which stocks to sell BEFORE you get the vaccine...

This is the same information I share with 8 of the top 10 money managers in the world.

And it's yours to view, free, right now.

Sincerely,

Joel Litman
Chief Investment Strategist
Altimetry Research

PS. The last time my unique stock analysis system gave an alert like this... was early February 2020.

I warned my corporate clients:

"Sentiment indicators have grown overly bullish... investors are not focused on risks. This increases the possibility of a negative shock."

Just a few weeks later, that negative shock came...

As the coronavirus forced lockdowns across America, the stock market pulled back 34% in a matter of days.

Anyone who listened to my February warning was prepared.

That's why I think it's very important you watch this video.

Because another crash is coming. And you can protect yourself ahead of time.

To accept this special invitation, click here.

 
Indexes Snapshot
Symbol Last Change %
Dow Jones Industrial Average 32297.02 +464.28 +1.44%
NASDAQ Composite 13068.83 -5.00 -0.04%
S&P 500 3898.81 +23.37 +0.60%
SPDR S&P 500 389.4000 +2.2300 +0.57%
iShares Russell 2000 ETF 227.14 +3.80 +1.67%
U.S. STOCK INDEXES

The June NASDAQ 100 was higher overnight as it extends the rally off last-Friday's low. The high-range trade sets the stage for a steady to higher opening when the day session begins trading. Stochastics and the RSI are neutral to bullish signaling that sideways to higher prices are possible near-term. Closes above the 50-day moving average crossing at 13,131.63 would signal that a short-term low has been posted. If June renews the decline off February's high, the 25% retracement level of the March-February-rally crossing at 12,146.81 is the next downside target. First resistance is the 50-day moving average crossing at 13,131.63. Second resistance is the February 25th high crossing at 13,337.50. First support is last-Friday's low crossing at 12,200.00. Second support is the 25% retracement level of the March-February-rally crossing at 12,146.81.

The June S&P 500 was higher overnight as it extends the rally off last-Thursday's low. The high-range overnight trade sets the stage for a steady to higher opening when the day session begins trading later this morning. Stochastics and the RSI are neutral to bullish signaling that sideways to higher prices are possible near-term. If June extends the rally off last-Thursday's low, February's high crossing at 3947.75 is the next upside target. Closes below the 50-day moving average crossing at 3820.40 are needed to confirm that a short-term top has been posted. First resistance is the February 25th high crossing at 3924.50. Second resistance is February's high crossing at 3947.75. First support is last-Thursday's low crossing at 3710.50. Second support is February's low crossing at 3648.00.



Thank you!

Thank you for subscribing to Market Commentary from INO.com.

You can modify your email preferences or unsubscribe here.

INO.com, Inc. | 228 Park Avenue South, Suite 320 | New York, New York 10003

U.S. Government Required Disclaimer - Commodity Futures Trading Commission Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results

These results are based on simulated or hypothetical performance results that have certain inherent limitations. Unlike the results shown in an actual performance record, these results do not represent actual trading. Also, because these trades have not actually been executed, these results may have under-or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity. Simulated or hypothetical trading programs in general are also subject to the fact that they are designed with the benefit of hindsight. No representation is being made that any account will or is likely to achieve profits or losses similar to these being shown.

All trades, patterns, charts, systems, etc., discussed in this message and the product materials are for illustrative purposes only and not to be construed as specific advisory recommendations. All ideas and material presented are entirely those of the author and do not necessarily reflect those of the publisher or INO.com. No system or methodology has ever been developed that can guarantee profits or ensure freedom from losses. No representation or implication is being made that using the methodology or system will generate profits or ensure freedom from losses. The testimonials and examples used herein are exceptional results, which do not apply to the average member, and are not intended to represent or guarantee that anyone will achieve the same or similar results. Each individual's success depends on his or her background, dedication, desire, and motivation.

No comments:

Post a Comment